Status:
COMPLETED
An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this observational study is to evaluate the safety and efficacy of modern insulins after switch from any other anti-diabetic treatment under normal clinical...
Eligibility Criteria
Inclusion
- Type 1 or type 2 diabetes
- Treatment with any diabetes treatment other than NovoMix® 30, Levemir® and/or NovoRapid®
- Selection will be at the discretion of the individual physician
Exclusion
- Current treatment with Levemir®, NovoMix® 30 and/or NovoRapid®
- Previous enrolled in this study
- Hypersensitivity to Levemir®, NovoMix® 30 and/or NovoRapid® or to any of the excipients
- Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months
Key Trial Info
Start Date :
February 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
5926 Patients enrolled
Trial Details
Trial ID
NCT00698269
Start Date
February 1 2008
End Date
August 1 2009
Last Update
October 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Riyadh, Saudi Arabia, 3542